Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318 clinical trials
Also written IBI318.
How each study uses Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI318
- 5
Studies by the year they started
6 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Innovent Biologics (Suzhou) Co. Ltd. (5) · Hunan Province Tumor Hospital (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.RecruitingPhase 2Hunan Province Tumor HospitalNCT04777084Written as IBI318How we know
- Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT04611321Written as IBI318How we know
- A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04635527Written as IBI318How we know
- Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT04602065Written as IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)How we know
- Study of IBI318 in Participants With Advanced MalignanciesCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT03875157Written as IBI318How we know
- A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04672928Written as IBI318How we know